CAR-T Cell Therapy Targeted Non-Hodgkin's Lymphoma: Clinical Development and Challenge
DOI:
https://doi.org/10.54097/sbwqcm19Keywords:
CAR-T cell therapy, Non-Hodgkin's Lymphoma, Development, Challenge.Abstract
Non-Hodgkin's lymphoma incidence has been rising worldwide in last few years. And the dismal prognosis following treatment to cure relapsed or resistant T-cell lymphoma and B-cell malignancies. Today, this therapy has already achieved incredible results with the field of non-Hodgkin's lymphoma. It becomes a new pillar in the treatment of cancer and shows great promise. Recently, there have been a number of new clinical studies and technology discoveries that have led to significant clinical responses to this therapy in certain subpopulations of Non-Hodgkin's Lymphoma. However, there are still many structural and functional challenges that limit the therapeutic efficacy of this therapy. Therefore, new strategies and ideas are needed to overcome the current challenges. The most recent developments and clinical trial findings on this therapy's effectiveness in treating NHL are covered in this review, as well as discussing the limitations of this therapy and the current solutions and strategies to address them.
Downloads
References
Chu, Y., Lamb, M., Cairo, M. S., & Lee, D. A. (2022). The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL). Current Treatment Options in Oncology, 23 (3), 381 – 403. https: //doi.org/10.1007/s11864 - 021 - 00932 - 2.
Hochberg, J., Flower, A., Brugieres, L., & Cairo, M. S. (2018). NHL in adolescents and young adults: A unique population. Pediatric Blood & Cancer, 65 (8). https: //doi.org/10.1002/pbc.27073.
Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: current limitations and potential strategies. Blood Cancer Journal, 11 (4). https: //doi.org/10.1038/s41408 - 021 - 00459 - 7.
Jogalekar, M. P., Rajendran, R. L., Khan, F., Dmello, C., Gangadaran, P., & Ahn, B.-C. (2022). CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.925985.
Albinger, N., Hartmann, J., & Ullrich, E. (2021). Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Therapy, 28(9), 513–527. https://doi.org/10.1038/s41434 - 021 - 00246 - w.
Wei, J., Xiao, M., Mao, Z., Wang, N., Cao, Y., Xiao, Y., Meng, F., Sun, W., Wang, Y., Yang, X., Chen, L., Zhang, Y., Zhu, H., Zhang, S., Zhang, T., Zhou, J., & Huang, L. (2022). Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT. Signal Transduction and Targeted Therapy, 7 (1). https: //doi.org/10.1038/s41392 - 022 - 00924 - 0.
Nguyen, T. T., Thanh Nhu, N., Chen, C., & Lin, C. (2023). Effectiveness and safety of CD22 and CD19 dual‐targeting chimeric antigen receptor T‐cell therapy in patients with relapsed or refractory B‐cell malignancies: A meta‐analysis. Cancer Medicine, 12 (18), 18767 – 18785. https: //doi.org/10.1002/cam4.6497.
Zhang, J., Hu, Y., Yang, J., Li, W., Zhang, M., Wang, Q., Zhang, L., Wei, G., Tian, Y., Zhao, K., Chen, A., Tan, B., Cui, J., Li, D., Li, Y., Qi, Y., Wang, D., Wu, Y., Li, D., & Du, B. (2022). Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature, 609 (7926), 369 – 374. https: //doi.org/10.1038/s41586 - 022 - 05140 - y.
Xia, B., Lin, K., Wang, X., Chen, F., Zhou, M., Li, Y., Lin, Y., Qiao, Y., Li, R., Zhang, W., He, X., Zou, F., Li, L., Lu, L., Chen, C., Li, W., Zhang, H., & Liu, B. (2023). Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment. Molecular Therapy - Oncolytics, 30, 86 – 102. https://doi.org/10.1016/j.omto.2023.07.007.
Iżykowska, K., Rassek, K., Korsak, D., & Przybylski, G. K. (2020). Novel targeted therapies of T cell lymphomas. Journal of Hematology & Oncology, 13 (1). https: //doi.org/10.1186/s13045 – 020 – 01006 - w.
Rouce, R. H., Hill, L. C., Smith, T. S., Yang, L., Boriskie, B., Srinivasan, M., Zhang, H., Perconti, S., Mehta, B., Dakhova, O., Grilley, B. J., Heslop, H. E., Brenner, M. K., & Mamonkin, M. (2021). Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma. Blood, 138(Supplement 1), 654 – 654. https: //doi.org/10.1182/blood - 2021 - 154142.
Voorhees, T. J., Ghosh, N., Grover, N., Block, J., Cheng, C., Morrison, K., Ivanova, A., Dotti, G., Serody, J., Savoldo, B., & Beaven, A. W. (2020). Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy. Blood Advances, 4 (23), 5925 – 5928. https://doi.org/10.1182/bloodadvances.2020003218.
Chu, Y., Lamb, M., Cairo, M. S., & Lee, D. A. (2022). The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL). Current Treatment Options in Oncology, 23 (3), 381 – 403. https: //doi.org/10.1007/s11864 - 021 - 00932 - 2.
Cheng, J., Liu, M., & Zhang, J. (2023). Intelligent tunable CAR-T cell therapy leads the new trend. Synthetic and Systems Biotechnology, 8 (4), 606 – 609. https: //doi.org/10.1016/j.synbio.2023.09.001.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
